Market Overview

Navidea to Present Data from Lymphoseek Studies at RSNA, CTRC-AACR Meetings

Related NAVB
European Commission Approves Navidea's Sentinel Lymph Node Detection Agent Lymphoseek
Navidea Receives $1.1M PDUFA Filing Fee Refund For Award Of Orphan Drug Status; Platinum Partners Reaffirms Commitment To Line Of Credit

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that data from its Lymphoseek^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

Posted-In: News

 

Related Articles (NAVB)

Around the Web, We're Loving...

Get Benzinga's Newsletters